157 related articles for article (PubMed ID: 38715057)
1. Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells.
Zhong P; Nakata K; Oyama K; Higashijima N; Sagara A; Date S; Luo H; Hayashi M; Kubo A; Wu C; He S; Yamamoto T; Koikawa K; Iwamoto C; Abe T; Ikenaga N; Ohuchida K; Morisaki T; Oda Y; Kuba K; Nakamura M
J Exp Clin Cancer Res; 2024 May; 43(1):138. PubMed ID: 38715057
[TBL] [Abstract][Full Text] [Related]
2. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1.
Zhang Z; Song B; Wei H; Liu Y; Zhang W; Yang Y; Sun B
Drug Resist Updat; 2024 Mar; 73():101040. PubMed ID: 38228036
[TBL] [Abstract][Full Text] [Related]
3. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
4. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
Yamamoto K; Venida A; Yano J; Biancur DE; Kakiuchi M; Gupta S; Sohn ASW; Mukhopadhyay S; Lin EY; Parker SJ; Banh RS; Paulo JA; Wen KW; Debnath J; Kim GE; Mancias JD; Fearon DT; Perera RM; Kimmelman AC
Nature; 2020 May; 581(7806):100-105. PubMed ID: 32376951
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance.
Deng Y; Xia X; Zhao Y; Zhao Z; Martinez C; Yin W; Yao J; Hang Q; Wu W; Zhang J; Yu Y; Xia W; Yao F; Zhao D; Sun Y; Ying H; Hung MC; Ma L
Nat Commun; 2021 Dec; 12(1):7041. PubMed ID: 34873175
[TBL] [Abstract][Full Text] [Related]
6. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
7. Selective autophagy of MHC-I promotes immune evasion of pancreatic cancer.
Yamamoto K; Venida A; Perera RM; Kimmelman AC
Autophagy; 2020 Aug; 16(8):1524-1525. PubMed ID: 32459143
[TBL] [Abstract][Full Text] [Related]
8. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
9. Ameliorative Effect of Hesperidin Against Motion Sickness by Modulating Histamine and Histamine H1 Receptor Expression.
Deshetty UM; Tamatam A; Bhattacharjee M; Perumal E; Natarajan G; Khanum F
Neurochem Res; 2020 Feb; 45(2):371-384. PubMed ID: 31782104
[TBL] [Abstract][Full Text] [Related]
10. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
Henry KE; Mack KN; Nagle VL; Cornejo M; Michel AO; Fox IL; Davydova M; Dilling TR; Pillarsetty N; Lewis JS
Mol Cancer Ther; 2021 Oct; 20(10):2026-2034. PubMed ID: 34349003
[TBL] [Abstract][Full Text] [Related]
11. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.
Wouters MM; Balemans D; Van Wanrooy S; Dooley J; Cibert-Goton V; Alpizar YA; Valdez-Morales EE; Nasser Y; Van Veldhoven PP; Vanbrabant W; Van der Merwe S; Mols R; Ghesquière B; Cirillo C; Kortekaas I; Carmeliet P; Peetermans WE; Vermeire S; Rutgeerts P; Augustijns P; Hellings PW; Belmans A; Vanner S; Bulmer DC; Talavera K; Vanden Berghe P; Liston A; Boeckxstaens GE
Gastroenterology; 2016 Apr; 150(4):875-87.e9. PubMed ID: 26752109
[TBL] [Abstract][Full Text] [Related]
12. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
[TBL] [Abstract][Full Text] [Related]
13. Integrative genomic analyses of the histamine H1 receptor and its role in cancer prediction.
Wang M; Wei X; Shi L; Chen B; Zhao G; Yang H
Int J Mol Med; 2014 Apr; 33(4):1019-26. PubMed ID: 24535227
[TBL] [Abstract][Full Text] [Related]
14. Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.
Bazhin AV; von Ahn K; Fritz J; Bunge H; Maier C; Isayev O; Neff F; Siveke JT; Karakhanova S
Oncoimmunology; 2022; 11(1):2043037. PubMed ID: 35251770
[TBL] [Abstract][Full Text] [Related]
15. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
16. Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade.
Gu SS; Zhang W; Wang X; Jiang P; Traugh N; Li Z; Meyer C; Stewig B; Xie Y; Bu X; Manos MP; Font-Tello A; Gjini E; Lako A; Lim K; Conway J; Tewari AK; Zeng Z; Sahu AD; Tokheim C; Weirather JL; Fu J; Zhang Y; Kroger B; Liang JH; Cejas P; Freeman GJ; Rodig S; Long HW; Gewurz BE; Hodi FS; Brown M; Liu XS
Cancer Discov; 2021 Jun; 11(6):1524-1541. PubMed ID: 33589424
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer cell migration.
Park C; Lee JW; Kim K; Seen DS; Jeong JY; Huh WK
Sci Rep; 2023 Feb; 13(1):1894. PubMed ID: 36732336
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer.
Zhang Y; Chandra V; Riquelme Sanchez E; Dutta P; Quesada PR; Rakoski A; Zoltan M; Arora N; Baydogan S; Horne W; Burks J; Xu H; Hussain P; Wang H; Gupta S; Maitra A; Bailey JM; Moghaddam SJ; Banerjee S; Sahin I; Bhattacharya P; McAllister F
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32860704
[TBL] [Abstract][Full Text] [Related]
19. Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer.
Fernández-Nogueira P; Noguera-Castells A; Fuster G; Recalde-Percaz L; Moragas N; López-Plana A; Enreig E; Jauregui P; Carbó N; Almendro V; Gascón P; Bragado P; Mancino M
Cancer Lett; 2018 Jun; 424():70-83. PubMed ID: 29548821
[TBL] [Abstract][Full Text] [Related]
20. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.
Hiraoka N; Ino Y; Hori S; Yamazaki-Itoh R; Naito C; Shimasaki M; Esaki M; Nara S; Kishi Y; Shimada K; Nakamura N; Torigoe T; Heike Y
Cancer Sci; 2020 Aug; 111(8):3057-3070. PubMed ID: 32495519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
